Advanced Enzyme FY26: ₹746 Cr revenue, ₹1.35 dividend

Results approved at May 9 board meeting

Advanced Enzyme Technologies said its Board of Directors met on May 09, 2026 to approve audited standalone and consolidated financial results for the year ended March 31, 2026, along with the audited Q4 FY26 numbers. The approvals were accompanied by a set of capital allocation and governance decisions that investors typically track around annual results. Alongside the financial statements, the company also outlined dividend plans and provided updates on key appointments. The disclosures were positioned under regulatory communication to stock exchanges.

Consolidated FY26 performance: revenue and profit rose

For FY26, consolidated revenue from operations rose to ₹745.76 crore from ₹636.91 crore in FY25. Consolidated net profit for the year increased to ₹173.61 crore from ₹133.97 crore in the previous year. Total comprehensive income was reported at ₹268.42 crore compared with ₹152.80 crore earlier. The company also disclosed that FY26 profit margin was 23.26% based on the consolidated numbers it shared.

Q4 FY26 snapshot: higher revenue, lower other income

In Q4 FY26, revenue from operations was ₹203.37 crore versus ₹167.18 crore in Q4 FY25. Other income for the quarter was ₹7.23 crore compared with ₹8.75 crore a year ago. Total income in Q4 FY26 came in at ₹210.60 crore against ₹175.92 crore in Q4 FY25. Total expenses for Q4 FY26 were reported at ₹150.90 crore, compared with ₹132.46 crore in Q4 FY25.

Standalone FY26: revenue and net profit also improved

On a standalone basis, revenue from operations increased to ₹452.77 crore from ₹351.41 crore in FY25. Standalone net profit for the year rose to ₹131.81 crore from ₹102.42 crore previously. The company presented the standalone numbers separately from the consolidated performance, reflecting how its parent entity performed on its own.

Dividend: ₹1.35 final dividend recommended, interim deferred

The board recommended a final dividend of ₹1.35 per equity share for FY26, described as 67.5% on the face value of ₹2 per share. The final dividend is subject to shareholder approval at the ensuing 37th Annual General Meeting. The company also said the board decided to defer declaration of an interim dividend, citing the need to preserve capital flexibility for evaluating potential strategic avenues and corporate actions aimed at long-term shareholder value.

Exceptional items and Labour Code impact

The consolidated results for FY26 included exceptional items amounting to a net credit of ₹11.36 crore. This included a reversal of a provision of ₹15.96 crore related to a lawsuit against Advanced Supplementary Technologies Corporation (U.S.A.), following a favourable direction by the United States Court of Appeals. The company said this was partially offset by an additional foreign exchange impact of ₹0.18 crore in Q4 FY26. It also recognised an incremental impact of ₹4.63 crore (gratuity) and ₹0.15 crore (compensated absences) under exceptional items in consolidated results, linked to the Government of India’s notification of four Labour Codes on November 21, 2025. On a standalone basis, an exceptional item of ₹3.86 crore was recognised on account of Labour Code changes.

Balance sheet: assets and equity increased year-on-year

On a consolidated basis, total assets were ₹1,838.76 crore as at March 31, 2026, compared with ₹1,621.35 crore as at March 31, 2025. Consolidated total equity increased to ₹1,683.12 crore from ₹1,468.67 crore over the same period. On a standalone basis, total assets were ₹803.64 crore versus ₹688.63 crore, while total equity rose to ₹709.62 crore from ₹629.34 crore.

Board decisions: director roles and auditor reappointment

The board approved the re-appointment of Mr. Mukund Madhusudan Kabra (DIN: 00148294) as Whole Time Director for a further term of five years effective April 01, 2027 to March 31, 2032, subject to shareholder approval at the 37th AGM. It also approved the appointment of Mr. Pradip Bhailal Shah (DIN: 01225582) as an Additional Director (Independent) effective June 12, 2026, for a five-year term up to June 11, 2031, subject to member approval. The board further approved the reappointment of M S K A & Associates LLP, Chartered Accountants (FRN: 105047W/W101187) as statutory auditors for a second term of five consecutive years, from the conclusion of the 37th AGM till the conclusion of the 42nd AGM. The statutory auditors issued an unmodified audit opinion on both standalone and consolidated FY26 results.

ESOP allotment and share capital change

The board approved the allotment of 49,350 equity shares of face value ₹2 per share under the Advanced Enzyme Technologies Limited Employees Stock Options Scheme 2022. Following this allotment, paid-up share capital increased from ₹22.39 crore (11,19,26,800 equity shares) to ₹22.40 crore (11,19,76,150 equity shares). The disclosure quantified both the rupee amount and the number of shares outstanding after the ESOP-related issuance.

Investor call details and trading window update

Advanced Enzyme announced a conference call for analysts and investors to discuss the financial results for the quarter and year ended March 31, 2026. The call is scheduled for Tuesday, May 12, 2026 at 09:00 hours IST, with primary dial-in numbers +91 86 3416 8438 / +91 86 4536 6489 and participant PIN (International) 4773312#. The management participants listed were Mr. Mukund Kabra (Whole-time Director) and Mr. Beni Prasad Rauka (Chief Financial Officer). The investor relations contact shared was Ronak Saraf (ir@advancedenzymes.com, +91 86578 64146). Separately, the company said the trading window remained closed from March 26, 2026 until May 11, 2026, in line with governance protocols.

Key numbers at a glance

Why these disclosures matter for shareholders

The FY26 release combines earnings, dividend recommendations, and governance updates in one set of board outcomes, which can shape how investors assess capital return and oversight. The decision to recommend a final dividend while deferring an interim dividend was explicitly linked to retaining capital flexibility for potential strategic actions. The exceptional-item detail also clarifies what portion of reported performance includes one-offs, including the provision reversal and Labour Code-related impacts. The ESOP allotment and resulting share capital change are relevant for tracking incremental dilution and the updated outstanding share count. The scheduled analyst call adds a formal forum for management discussion of the audited numbers, using the dial-in details shared in the disclosure.

Conclusion

Advanced Enzyme Technologies reported higher FY26 revenue and profit on both consolidated and standalone bases and recommended a ₹1.35 per share final dividend, subject to shareholder approval at the 37th AGM. Investors will also track follow-through on the director and auditor approvals, the ESOP-related increase in paid-up capital, and the management commentary expected during the May 12, 2026 conference call.